DK2948148T3 - Metoder til behandling af autoimmune, åndedræts- og betændelsesforstyrrelser ved inhalation af roflumilast n-oxid - Google Patents
Metoder til behandling af autoimmune, åndedræts- og betændelsesforstyrrelser ved inhalation af roflumilast n-oxid Download PDFInfo
- Publication number
- DK2948148T3 DK2948148T3 DK14705875.4T DK14705875T DK2948148T3 DK 2948148 T3 DK2948148 T3 DK 2948148T3 DK 14705875 T DK14705875 T DK 14705875T DK 2948148 T3 DK2948148 T3 DK 2948148T3
- Authority
- DK
- Denmark
- Prior art keywords
- roflumilast
- autoimmune
- inhalation
- respiratory
- oxide
- Prior art date
Links
- 208000023275 Autoimmune disease Diseases 0.000 title 1
- 230000001363 autoimmune Effects 0.000 title 1
- 208000027866 inflammatory disease Diseases 0.000 title 1
- 230000000241 respiratory effect Effects 0.000 title 1
- 208000023504 respiratory system disease Diseases 0.000 title 1
- PCGSQNPMMSALEJ-UHFFFAOYSA-N roflumilast n-oxide Chemical compound ClC1=C[N+]([O-])=CC(Cl)=C1NC(=O)C1=CC=C(OC(F)F)C(OCC2CC2)=C1 PCGSQNPMMSALEJ-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Dispersion Chemistry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN354CH2013 | 2013-01-28 | ||
| IN355CH2013 | 2013-01-28 | ||
| PCT/IB2014/058617 WO2014115127A1 (en) | 2013-01-28 | 2014-01-28 | Methods of treating autoimmune, respiratory and inflammatory disorders by inhalation of roflumilast n-oxide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2948148T3 true DK2948148T3 (da) | 2020-10-26 |
Family
ID=54196705
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK14705875.4T DK2948148T3 (da) | 2013-01-28 | 2014-01-28 | Metoder til behandling af autoimmune, åndedræts- og betændelsesforstyrrelser ved inhalation af roflumilast n-oxid |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US9649302B2 (da) |
| EP (2) | EP3763366A1 (da) |
| JP (3) | JP6426624B2 (da) |
| KR (2) | KR20200105983A (da) |
| CN (3) | CN110403922A (da) |
| AU (2) | AU2014208359B2 (da) |
| BR (1) | BR112015017784A2 (da) |
| CA (1) | CA2897464C (da) |
| CY (1) | CY1123478T1 (da) |
| DK (1) | DK2948148T3 (da) |
| EA (1) | EA033113B1 (da) |
| ES (1) | ES2828070T3 (da) |
| HR (1) | HRP20201711T1 (da) |
| HU (1) | HUE052275T2 (da) |
| IL (2) | IL240154B (da) |
| LT (1) | LT2948148T (da) |
| NZ (1) | NZ710726A (da) |
| PL (1) | PL2948148T3 (da) |
| PT (1) | PT2948148T (da) |
| RS (1) | RS60985B1 (da) |
| SG (2) | SG10201911395UA (da) |
| SI (1) | SI2948148T1 (da) |
| SM (1) | SMT202000585T1 (da) |
| WO (1) | WO2014115127A1 (da) |
| ZA (1) | ZA201505600B (da) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9757395B2 (en) | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
| US9757529B2 (en) | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
| DK2948148T3 (da) * | 2013-01-28 | 2020-10-26 | Incozen Therapeutics Pvt Ltd | Metoder til behandling af autoimmune, åndedræts- og betændelsesforstyrrelser ved inhalation af roflumilast n-oxid |
| WO2014178891A1 (en) | 2013-04-30 | 2014-11-06 | Otitopic Inc. | Dry powder formulations and methods of use |
| WO2018167142A1 (en) * | 2017-03-16 | 2018-09-20 | Takeda Gmbh | Treatment of idiopathic pulmonary fibrosis |
| US12011437B1 (en) | 2017-06-07 | 2024-06-18 | Arcutis Biotherapeutics, Inc. | Roflumilast formulations with an improved pharmacokinetic profile |
| US9895359B1 (en) | 2017-06-07 | 2018-02-20 | Arcutis, Inc. | Inhibition of crystal growth of roflumilast |
| US12042487B2 (en) | 2018-11-16 | 2024-07-23 | Arcutis Biotherapeutics, Inc. | Method for reducing side effects from administration of phosphodiesterase-4 inhibitors |
| US11129818B2 (en) | 2017-06-07 | 2021-09-28 | Arcutis Biotherapeutics, Inc. | Topical roflumilast formulation having improved delivery and plasma half life |
| US20200155524A1 (en) | 2018-11-16 | 2020-05-21 | Arcutis, Inc. | Method for reducing side effects from administration of phosphodiesterase-4 inhibitors |
| US20210161870A1 (en) | 2017-06-07 | 2021-06-03 | Arcutis Biotherapeutics, Inc. | Roflumilast formulations with an improved pharmacokinetic profile |
| US10786456B2 (en) | 2017-09-22 | 2020-09-29 | Otitopic Inc. | Inhaled aspirin and magnesium to treat inflammation |
| CN115919780A (zh) | 2017-09-22 | 2023-04-07 | 维克图拉公司 | 含有硬脂酸镁的干粉组合物 |
| US11534493B2 (en) | 2017-09-22 | 2022-12-27 | Arcutis Biotherapeutics, Inc. | Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solvents |
| GB201807286D0 (en) * | 2018-05-03 | 2018-06-20 | Dalsgaard Carl Johan | New use |
| KR20210044191A (ko) | 2018-06-04 | 2021-04-22 | 아큐티스, 인크. | 로플루밀라스트 피부 침투 지연 시간의 개선 방법 및 제형 |
| EP3860580A4 (en) * | 2018-10-01 | 2022-07-20 | Kindeva Drug Delivery L.P. | FORMULATION AND AEROSOL CARTRIDGES, INHALATORS AND THE LIKE CONTAINING THE FORMULATION |
| CN120285204A (zh) * | 2018-10-23 | 2025-07-11 | G·E·霍格 | 用于治疗肺的组合物和方法 |
| CN111467498A (zh) * | 2020-05-14 | 2020-07-31 | 王兆霖 | 药物组合物制剂 |
| CN116157688A (zh) * | 2020-07-31 | 2023-05-23 | 基因泰克公司 | 用于治疗炎症性呼吸系统疾病的恶化的方法 |
| MX2023006602A (es) | 2020-12-04 | 2023-08-07 | Arcutis Biotherapeutics Inc | Formulación tópica de roflumilast que tiene propiedades antimicoticas. |
| CR20240063A (es) * | 2021-07-09 | 2024-04-25 | Astrazeneca Pharmaceuticals Lp | Composiciones, métodos y sistemas para la administración de fármacos en aerosol |
| IL313866A (en) | 2021-12-28 | 2024-08-01 | Arcutis Biotherapeutics Inc | Topical roflomilest spray foams |
| GB2614901A (en) * | 2022-01-21 | 2023-07-26 | Nanopharm Ltd | Inhalable formulations |
| JP2025530005A (ja) | 2022-09-15 | 2025-09-09 | アーキュティス・バイオセラピューティクス・インコーポレーテッド | ロフルミラスト及び大量のロフルミラストを溶解可能な溶媒の医薬組成物 |
| CN117224482A (zh) * | 2023-09-07 | 2023-12-15 | 苏州易合医药有限公司 | 一种用于治疗ipf疾病的吸入制剂及其制备方法 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2165192C (en) * | 1993-07-02 | 2001-04-24 | Hermann Amschler | Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors |
| BRPI0013478B8 (pt) * | 1999-08-21 | 2016-12-27 | Altana Pharma Ag | medicamento compreendendo inibidor pde e uso de roflumilast |
| PE20011227A1 (es) | 2000-04-17 | 2002-01-07 | Chiesi Farma Spa | Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros |
| AU6196201A (en) | 2000-05-25 | 2001-12-03 | Merck Frosst Canada Inc | Fluoroalkoxy-substituted benzamide dichloropyridinyl n-oxide pde4 inhibitor |
| UA80393C2 (uk) * | 2000-12-07 | 2007-09-25 | Алтана Фарма Аг | Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці |
| PT1386630E (pt) | 2002-07-31 | 2006-09-29 | Chiesi Farma Spa | Inalador em po |
| US20060142308A1 (en) * | 2002-11-27 | 2006-06-29 | Atlanta Pharma Ag | Synergistic combination comprising roflumilast and formoterol |
| WO2004084894A1 (en) | 2003-03-28 | 2004-10-07 | Altana Pharma Ag | Synergistic combination comprising roflumilast and revatropate for the treatment of respiratory diseases |
| GB0321607D0 (en) * | 2003-09-15 | 2003-10-15 | Vectura Ltd | Manufacture of pharmaceutical compositions |
| CN101518532A (zh) * | 2004-02-06 | 2009-09-02 | Meda制药有限及两合公司 | 用于呼吸道疾病治疗的抗胆碱能药和4型磷酸二酯酶抑制剂的组合 |
| JP2007524699A (ja) * | 2004-02-27 | 2007-08-30 | アルタナ ファルマ アクチエンゲゼルシャフト | ロフルミラストとグリコピロニウムとの組合せ物 |
| WO2005107749A1 (en) | 2004-05-10 | 2005-11-17 | Altana Pharma Ag | Use of roflumilast for the prophylaxis or treatment of emphysema |
| WO2006094942A1 (en) * | 2005-03-08 | 2006-09-14 | Nycomed Gmbh | Roflumilast for the treatment of diabetes mellitus |
| EP2366393B1 (en) | 2005-04-19 | 2013-08-07 | Takeda GmbH | Roflumilast for the treatment of pulmonary hypertension |
| GB0523653D0 (en) | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
| CA2609429A1 (en) * | 2005-05-31 | 2006-12-07 | Boehringer Ingelheim International Gmbh | Medicament containing a betamimetic in conjunction with an anticholinergic and a pde iv inhibitor |
| NZ568349A (en) * | 2005-12-21 | 2011-05-27 | Meda Pharma Gmbh & Co Kg | Combination of anticholinergics, glucocorticoids, beta2-agonists, PDE 4 inhibitor and antileukotriene for the treatment of inflammatory diseases |
| JP2010530427A (ja) * | 2007-06-21 | 2010-09-09 | シェーリング コーポレイション | 多環式グアニン誘導体およびその使用方法 |
| TWI792140B (zh) * | 2009-05-29 | 2023-02-11 | 美商沛爾醫療股份有限公司 | 用於經由呼吸道遞送二或更多種活性藥劑的組成物、方法與系統 |
| WO2011163469A1 (en) | 2010-06-23 | 2011-12-29 | Teva Pharmaceutical Industries Ltd. | Hydrated form of anti-inflammatory roflumilast-n-oxide |
| EP2600829B1 (en) * | 2010-08-03 | 2017-06-14 | Chiesi Farmaceutici S.p.A. | Pharmaceutical formulation comprising a phosphodiesterase inhibitor |
| CN103570610B (zh) * | 2012-07-18 | 2017-08-11 | 重庆华邦制药有限公司 | 一种罗氟司特微粒的制备方法 |
| DK2948148T3 (da) * | 2013-01-28 | 2020-10-26 | Incozen Therapeutics Pvt Ltd | Metoder til behandling af autoimmune, åndedræts- og betændelsesforstyrrelser ved inhalation af roflumilast n-oxid |
-
2014
- 2014-01-28 DK DK14705875.4T patent/DK2948148T3/da active
- 2014-01-28 CA CA2897464A patent/CA2897464C/en active Active
- 2014-01-28 SG SG10201911395UA patent/SG10201911395UA/en unknown
- 2014-01-28 PT PT147058754T patent/PT2948148T/pt unknown
- 2014-01-28 RS RS20201290A patent/RS60985B1/sr unknown
- 2014-01-28 PL PL14705875T patent/PL2948148T3/pl unknown
- 2014-01-28 NZ NZ710726A patent/NZ710726A/en not_active IP Right Cessation
- 2014-01-28 HR HRP20201711TT patent/HRP20201711T1/hr unknown
- 2014-01-28 LT LTEP14705875.4T patent/LT2948148T/lt unknown
- 2014-01-28 EP EP20192104.6A patent/EP3763366A1/en not_active Withdrawn
- 2014-01-28 CN CN201910738378.4A patent/CN110403922A/zh active Pending
- 2014-01-28 EP EP14705875.4A patent/EP2948148B1/en active Active
- 2014-01-28 CN CN201480006017.6A patent/CN104994854A/zh active Pending
- 2014-01-28 SG SG11201505835QA patent/SG11201505835QA/en unknown
- 2014-01-28 EA EA201591269A patent/EA033113B1/ru unknown
- 2014-01-28 AU AU2014208359A patent/AU2014208359B2/en not_active Ceased
- 2014-01-28 WO PCT/IB2014/058617 patent/WO2014115127A1/en not_active Ceased
- 2014-01-28 KR KR1020207025499A patent/KR20200105983A/ko not_active Ceased
- 2014-01-28 KR KR1020207000733A patent/KR102154104B1/ko not_active Expired - Fee Related
- 2014-01-28 SI SI201431691T patent/SI2948148T1/sl unknown
- 2014-01-28 HU HUE14705875A patent/HUE052275T2/hu unknown
- 2014-01-28 CN CN201910738379.9A patent/CN110464724A/zh active Pending
- 2014-01-28 BR BR112015017784A patent/BR112015017784A2/pt not_active IP Right Cessation
- 2014-01-28 SM SM20200585T patent/SMT202000585T1/it unknown
- 2014-01-28 ES ES14705875T patent/ES2828070T3/es active Active
- 2014-01-28 US US14/166,463 patent/US9649302B2/en not_active Expired - Fee Related
- 2014-01-28 JP JP2015554296A patent/JP6426624B2/ja not_active Expired - Fee Related
-
2015
- 2015-07-26 IL IL240154A patent/IL240154B/en active IP Right Grant
- 2015-08-04 ZA ZA2015/05600A patent/ZA201505600B/en unknown
-
2017
- 2017-03-24 US US15/469,243 patent/US11103488B2/en active Active
-
2018
- 2018-06-25 JP JP2018119732A patent/JP2018168172A/ja active Pending
- 2018-07-10 AU AU2018205077A patent/AU2018205077B2/en not_active Ceased
-
2020
- 2020-02-07 JP JP2020019696A patent/JP7015331B2/ja not_active Expired - Fee Related
- 2020-02-16 IL IL272701A patent/IL272701B2/en unknown
- 2020-10-20 CY CY20201100990T patent/CY1123478T1/el unknown
-
2021
- 2021-07-19 US US17/443,005 patent/US20220008400A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2948148T3 (da) | Metoder til behandling af autoimmune, åndedræts- og betændelsesforstyrrelser ved inhalation af roflumilast n-oxid | |
| DK2830662T3 (da) | Fremgangsmåder til behandlng af hårtabsforstyrrelser | |
| DK3421042T3 (da) | Indånding af nitrogenoxid til behandling af luftvejssygdomme | |
| HRP20181227T1 (hr) | Metode za liječenje atopijskog dermatitisa primjenom antagonista il-4r | |
| DK3076967T3 (da) | Fremgangsmåder til behandling af residuelle symptomer på skizofreni | |
| PL3139979T3 (pl) | Jednostka, nebulizator i sposób | |
| DK2895156T3 (da) | Fremgangsmåde til fremstilling af terapeutiske nanopartikler | |
| DK3265085T3 (da) | Fremgangsmåder til behandling af forstyrrelser med abnorme ufrivillige bevægelser | |
| DK3461240T3 (da) | Fremgangsmåder, systemer og apparat til cyklotronfremstilling af technetium-99m | |
| DK2726511T3 (da) | Sammensætninger, anvendelser og fremgangsmåder til behandling af stofskiftesygdomme og -lidelser | |
| DK2905062T3 (da) | Apparat til behandling af udstødningsgas | |
| DK3811943T3 (da) | Forbindelse til anvendelse til behandling af øjenlidelser | |
| DK2967049T3 (da) | Metoder, forbindelser og sammensætninger til behandlingen af angiotensin relaterede sygdomme | |
| DK3054976T3 (da) | Anvendelse af semaphorin-4d-bindende molekyler til behandling af aterosklerose | |
| DK2961378T3 (da) | Fremgangsmåder til behandlingen af mitochondrisk sygdom | |
| LT3007726T (lt) | Tautopatijos gydymo būdai | |
| DK2897611T3 (da) | Fremgangsmåder til behandling af hepatitis c | |
| DK2961426T3 (da) | Behandling af sygdomme i centralnervesystemet ved intranasal indgivelse af immunoglobulin g | |
| DK3038656T3 (da) | Forbindelse af glycosaminoglycan, fremgangsmåde til fremstilling og anvendelse deraf | |
| DK2976072T3 (da) | Epinephrinfinpartikler og fremgangsmåder til anvendelse deraf til behandling af tilstande, der reagerer på epinephrin | |
| DK3632373T3 (da) | Inhalator | |
| DK2925317T3 (da) | CFTR-korrektor til behandling af genetiske forstyrrelser, der påvirker tværstribet muskel | |
| DK3116570T3 (da) | Inhalator | |
| EP2966908A4 (en) | POLICY AGREEMENT, USER DEVICE AND SERVER | |
| DK3035887T3 (da) | Inhalator |